Growth fraction in human brain tumors defined by the monoclonal antibody Ki-67

1987 ◽  
Vol 74 (2) ◽  
pp. 179-182 ◽  
Author(s):  
F. Giangaspero ◽  
C. Doglioni ◽  
M. T. Rivano ◽  
S. Pileri ◽  
J. Gerdes ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Brain Tumors ◽  
Human Brain ◽  
Growth Fraction ◽  
Ki 67 ◽  
Human Brain Tumors

Cell kinetics studies of human brain tumors by in vitro labeling using anti-BUdR monoclonal antibody

1988 ◽  
Vol 69 (3) ◽  
pp. 371-374 ◽  
Author(s):  
Takafumi Nishizaki ◽  
Tetsuji Orita ◽  
Masahide Saiki ◽  
Yasuhiro Furutani ◽  
Hideo Aoki
Keyword(s):  
Monoclonal Antibody ◽  
Brain Tumors ◽  
Human Brain ◽  
Intravenous Infusion ◽  
Reproductive Age ◽  
Proliferative Potential ◽  
Human Brain Tumor ◽  
Human Brain Tumors

✓ Since the development of a specific monoclonal antibody against the thymidine analogue bromodeoxyuridine (BUdR), many investigators have used intravenous infusion of BUdR to estimate the proliferative potential of human brain tumors. However, side effects such as the induction of cell mutation, latent virus promotion, or inhibition of cytodifferentiation cannot be ignored, and thus many workers hesitate to use it in patients, especially those with hepatic disease or of reproductive age. Furthermore, if BUdR remains in the deoxyribonucleic acid of tumor cells after injection, analysis of the effect of chemical and radiation therapy may not be evaluated correctly. In this report, in vitro BUdR labeling with an anti-BUdR antibody is compared with the in vivo methods described by previous authors. This method appears to be useful for determining the S-phase fraction of human brain tumor. It was more rapid, and was simple, safe, and reproducible as compared to the intravenous infusion method.

Quantitative studies of monoclonal antibody targeting to disialoganglioside GD2 in human brain tumors

1995 ◽  
Vol 22 (5) ◽  
pp. 419-426 ◽  
Author(s):  
Enud Arbit ◽  
Nai-Kong V. Cheung ◽  
Samuel D. J. Yeh ◽  
Farhad Daghighian ◽  
Jian Ju Zhang ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Brain Tumors ◽  
Human Brain ◽  
Human Brain Tumors ◽  
Quantitative Studies ◽  
Antibody Targeting

scholarly journals EXPRESSION OF ANTIGENS DEFINED BY THE MONOCLONAL ANTIBODY AT5 IN CULTURED NEURAL CELLS AND IN HUMAN BRAIN TUMORS OF GLIAL ORIGIN

1997 ◽  
Vol 18 (1) ◽  
pp. 7-19
Author(s):  
ALEXANDER A. PREOBRAZHENSKY ◽  
FRANCESCA ALOISI ◽  
VALERY M. BARABANOV ◽  
KARL SCHWECHHEIMER
Keyword(s):  
Monoclonal Antibody ◽  
Brain Tumors ◽  
Human Brain ◽  
Neural Cells ◽  
Human Brain Tumors

scholarly journals Monoclonal Antibody to Human Midkine Reveals Increased Midkine Expression in Human Brain Tumors

1999 ◽  
Vol 58 (5) ◽  
pp. 430-441 ◽  
Author(s):  
SHINSUKE KATO ◽  
KENJI ISHIHARA ◽  
TAKAO SHINOZAWA ◽  
HIROYUKI YAMAGUCHI ◽  
YOSHIYA ASANO ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Brain Tumors ◽  
Human Brain ◽  
Human Brain Tumors

Flow-cytometric DNA analysis and immunohistochemical measurement of Ki-67 and BUdR labeling indices in human brain tumors

1989 ◽  
Vol 70 (3) ◽  
pp. 379-384 ◽  
Author(s):  
Takafumi Nishizaki ◽  
Tetsuji Orita ◽  
Yasuhiro Furutani ◽  
Yukihide Ikeyama ◽  
Hideo Aoki ◽  
...  
Keyword(s):  
Brain Tumors ◽  
Human Brain ◽  
Malignant Glioma ◽  
Dna Analysis ◽  
Labeling Index ◽  
Ki 67 ◽  
Content Type ◽  
Dna Aneuploidy ◽  
Human Brain Tumors ◽  
Flow Cytometric

✓ Cell proliferation potential was assessed by measuring the labeling indices of the monoclonal antibody Ki-67 and of 5-bromodeoxyuridine (BUdR), and the cellular deoxyribonucleic acid (DNA) content in 48 human brain tumors. The diagnostic and prognostic value of flow-cytometric DNA analysis was also evaluated using ethanol-fixed paraffin-embedded BUdR-labeled specimens; these were the same specimens as were used for measuring the BUdR and Ki-67 labeling indices. Both the Ki-67 and the BUdR labeling indices correlated with the degree of malignancy estimated from conventional histological preparations. The Ki-67 labeling index was 1.7 times greater than the BUdR labeling index. The relationship of DNA aneuploidy to the labeling indices or to morphology in cases of glioma was examined. All of the tumors with an aneuploid line corresponded to malignant glioma classified by histological criteria, although malignant glioma did not always show DNA aneuploidy. In addition, the cases with aneuploid lines showed high BUdR and Ki-67 labeling indices. The cell kinetic data, which indicate the biological character of tumors, allowed prediction of the prognosis of the patients with gliomas. In contrast, despite the presence of an aneuploid line, three of 13 meningiomas showed a benign histological pattern without an aggressive clinical course, and neither the Ki-67 nor the BUdR labeling index was high. These results indicate an unequivocal relationship between DNA aneuploidy and clinical behavior; in general, both labeling indices may prove to be objective indicators of the outcome of patients with brain tumors.

Immunohistochemical studies on human brain tumors using anti-Leu 7 monoclonal antibody in paraffin-embedded specimens

1985 ◽  
Vol 66 (1) ◽  
pp. 75-77 ◽  
Author(s):  
M. Motoi ◽  
T. Yoshino ◽  
K. Hayashi ◽  
S. Nose ◽  
Y. Horie ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Brain Tumors ◽  
Human Brain ◽  
Human Brain Tumors ◽  
Immunohistochemical Studies ◽  
Leu 7

scholarly journals The Cycling Pool of Cells within Human Brain Tumors: In Situ Cytokinetics Using the Monoclonal Antibody Ki-67

1991 ◽  
Vol 18 (1) ◽  
pp. 12-17 ◽  
Author(s):  
Ana Maria Tsanaclis ◽  
Françoise Robert ◽  
Jean Michaud ◽  
Steven Brem
Keyword(s):  
Brain Tumors ◽  
Human Brain ◽  
Relative Proportion ◽  
Labeling Index ◽  
Specific Method ◽  
Low Grade ◽  
Ki 67 ◽  
Human Brain Tumors ◽  
Oncology Research ◽  
Acoustic Schwannoma

ABSTRACT:Brain tumor growth results from the relative proportion of cells contained in three populations: a) cycling/proliferative; b) quiescent (Go)/static, and c) terminally differentiated/dying. The cycling compartment can be detected by the mouse monoclonal Ki-67 antibody, an available, rapid, safe, sensitive, and specific method for immunostaining of proliferative cells. We report the Ki-67 labeling index (LI) in 48 brain tumors. Malignant brain tumors have elevated Lis, ranging from 6.0% to 56.9%: anaplastic astrocytoma, 8.0 ± 7.3; glioblastoma multiforme, 10.1 ±4.2; germinoma, 11.7; medulloblastoma, 13.1 ± 6.6; metastases, 40.3 ± 13.1. By contrast, slow-growing tumors showed lower values (P < .001), approaching 1%: acoustic schwannoma, 0.4 ± 0.6; pituitary adenoma, 1.3 ± 1.9; meningioma, 1.2 ± 1.2; low-grade astrocytoma, < 1; pilocytic astrocytoma, 5.6. Human brain tumors can therefore be ranked according to the percentage of cycling cells with the acoustic schwannoma among the least proliferative and the metastatic carcinoma among the most proliferative. Within a given histotype, the Ki-67 LI may have prognostic and therapeutic implications for the individual patient. Already important for neuro-oncology research, the Ki-67 labeling index should be added to the armamentarium of the clinical neuropathologist to complement the standard histopathologic diagnosis with a cytokinetic analysis of cellular proliferation.

Sign in / Sign up

Export Citation Format

Share Document